The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in children aged 4 and above. This is the first emergency allergy treatment ...
Hanna Newnham, 27, from Brighton, first noticed symptoms of cold urticaria - hives that appear after cold temperature ...
Mylan's settlement with drug wholesalers comes on the heels of the company reaching a $264 million settlement for consumers ...
Researchers at the University of Michigan in Ann Arbor, Michigan, found that using transepidermal water loss (TEWL) as the ...
During her freshman year, now-Weinberg senior Julia Auerbach was at Bob’s Pizza in Evanston when she witnessed someone go ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...
The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...
The global epinephrine auto-injector market is set for steady expansion, driven by the increasing prevalence of severe allergies worldwide. According to market projections, global sales of epinephrine ...
The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...
Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback